Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' pipeline of antiviral treatments.
Celyad, the former Cardio3 Biosciences, filed to make a $115 million debut on the Nasdaq, stretching its focus from heart treatments to the fast-growing field of cancer immunotherapy.
U.K. drugmaker GW Pharmaceuticals believes its cannabis-derived epilepsy treatment is on its way to Phase III success and FDA approval, moving its CEO to the U.S. as it builds a North American presence.
Intercept Pharmaceuticals, striving to launch the world's first treatment for a pervasive liver disease, spelled out its plans for a sizable Phase III study designed to secure an accelerated approval and help the company retain pole position in a potentially lucrative field.
Neil Woodford's new $1.2 billion fund and GlaxoSmithKline's VC unit have contributed to a $39 million Series C round in PsiOxus Therapeutics. The cash will allow PsiOxus to test its oncolytic virus together with a checkpoint inhibitor, a combination it thinks can make the immuno-oncology treatment effective against otherwise resistant targets.
Bluebird bio, developing a potential cure for a rare blood disorder, is angling for an accelerated approval as it works through clinical trials, setting out a regulatory framework that could get the gene therapy on the market sooner than expected.
Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its lead eczema program.
AstraZeneca's best bets for the future are mostly biological treatments. And to prepare for its growing dependence on biotech drugs, the U.K. drugmaker is spending $285 million on a new biologics manufacturing operation.
Sorrento Therapeutics, a frequent partner of billionaire biotech entrepreneur Patrick Soon-Shiong, launched a new subsidiary to advance its take on CAR-T therapies for cancer, taking a page from its patron as it tosses more and more irons in the R&D fire.
The commercial potential of NASH, a common liver disease with no approved treatments, has seemingly launched a thousand R&D ships around the industry. And Novo Nordisk, emboldened by an investigator-sponsored study, might be sitting on an effective therapy for the pervasive ailment with liraglutide, a blockbuster already approved for diabetes and obesity.
Boehringer Ingelheim has made a quick decision about Pharmaxis' non-alcoholic steatohepatitis (NASH) drug, striking a $250 million deal to buy the Phase I asset just two months after inking an option to acquire the program.
Celgene's expansive approach to partnering continues to bear fruit, as two of the Big Biotech's in-licensed treatments have been added to the FDA's fast-track program, promising a speedy regulatory review as each approaches Phase III.
Some of the leaders in the field will be gathering for a special FierceBiotech panel discussion on clinical trial design and execution for cancer drugs at the upcoming annual meeting of BIO in Philadelphia on June 16.
Eleven Biotherapeutics' top pipeline prospect bombed a late-stage study in dry eye disease, failing to beat out placebo and forcing the Third Rock Ventures-founded biotech to pivot its focus.
As growing demand for lab space in Cambridge, MA, threatens to price out startups, biotech foundry Third Rock Ventures is looking to make a splash in the neighborhood to give its seedlings access to one of the industry's most vibrant innovation hubs, Beta Boston reports.
Swedish-American biotech Cortendo is expanding its focus on rare endocrine diseases, buying a pair of Phase II treatments for acromegaly for a combined $35 million.
NantWorks, the nebulous empire of biotech billionaire Patrick Soon-Shiong, is handing over $90 million to partner Sorrento Therapeutics in exchange for a Phase III cancer drug heralded as a successor to the blockbuster Abraxane.
Reeling after the Phase IIb failure of its "breakthrough" gene therapy for heart failure, Celladon is slashing its budget and payroll, vowing to find a way forward that preserves value for its investors.
Amgen says it got the positive data it was looking for from a Phase II study of AMG 334, one of several experimental migraine drugs that share the same target and are in the running to compete against an old generation of drugs on the market.